Uric acid and the kidney: Urate transport, stone disease and progressive renal failure

Current Pharmaceutical Design

Volumn 11, Issue 32, 2005, Pages 4153-4159

  Capasso, G ^a   Jaeger, Ph ^b   Robertson, W G ^b,c   Unwin, Robert J ^b,c,d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b PASTEUR HOSPITAL   (France)

^c INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Kidney; Nephrolithiasis; Renal failure; Tamm Horsfall protein; Urate transport; Uric acid; Uromodulin

Indexed keywords

ALLOPURINOL; CARRIER PROTEIN; INSULIN; ORGANIC ANION TRANSPORTER; PROBENECID; PYRAZINAMIDE; PYRAZINOIC ACID; TAMM HORSFALL GLYCOPROTEIN; URATE; URIC ACID; URICOSURIC AGENT;

ANION EXCHANGE; CELL TRANSPORT; CHRONIC KIDNEY FAILURE; DISEASE COURSE; ELECTRIC POTENTIAL; GENETIC DISORDER; HUMAN; HYPERSENSITIVITY REACTION; HYPERURICEMIA; HYPERURICOSURIA; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; MEDULLARY SPONGE KIDNEY; MOLECULAR MECHANICS; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS;

ANIMALS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; HUMANS; HYPERURICEMIA; KIDNEY; KIDNEY CALCULI; KIDNEY FAILURE; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; URIC ACID;

EID: 27944470008     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774913219     Document Type: Review

References (63)

1. Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 1989; 86: 9412-6.
2. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116: 546-54.
3. Augoustides-Savvopoulou P, Papachristou F, Fairbanks LD, Dimitrakopoulos K, Marinaki AM, Simmonds HA. Partial hypoxanthine-guanine phosphoribosyltransferase deficiency as the unsuspected cause of renal disease spanning three generations: a cautionary tale. Pediatrics 2002; 109: E17.
4. Rafey MA, Lipkowitz MS, Leal-Pinto E, Abramson RG. Uric acid transport. Curr Opin Nephrol Hypertens 2003; 12: 511-6.
5. Feig DI, Nakagawa T, Karumanchi SA, Oliver WJ, Kang DH, Finch J, et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66: 281-7.
6. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-90.
7. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-97.
8. Roch-Ramel F, Guisan B. Renal Transport of Urate in Humans. News Physiol Sci 1999; 14: 80-4.
9. Greger R, Lang F, Deetjen P. Handling of uric acid by the rat kidney. I. Microanalysis of uric acid in proximal tubular fluid. Pflügers Arch 1971; 324: 279-87.
10. Cook MA, Adkinson JT, Lassiter WE, Gottschalk CW. Uric acid excretion by the rat kidney. Am J Physiol 1975; 229: 586-91.
11. Steele TH. Urate secretion in man: the pyrazinamide suppression test. Ann Intern Med 1973; 79: 734-7.
12. Roch-Ramel F, Werner D, Guisan B. Urate transport in brush-border membrane of human kidney. Am J Physiol 1994; 266: F797-805.
13. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-52.
14. Ullrich KJ, Fasold H, Rumrich G, Kloss S. Secretion and contraluminal uptake of dicarboxylic acids in the proximal convolution of rat kidney. Pflügers Arch 1984; 400: 241-9.
15. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15: 164-73.
16. Ullrich KJ, Rumrich G. Renal transport mechanisms for xenobiotics: chemicals and drugs. Clin Investig 1993; 71: 843-8.
17. Ullrich KJ, Rumrich G, Fritzsch G, Kloss S. Contraluminal para-aminohippurate (PAH) transport in the proximal tubule of the rat kidney. II. Specificity: aliphatic dicarboxylic acids. Pflügers Arch 1987; 408: 38-45.
18. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 1997; 272: 18526-9.
19. Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T, et al. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 2003; 63: 143-55.
20. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 2001; 59: 1277-86.
21. Ullrich KJ, Rumrich G. Luminal transport step of para-aminohippurate (PAH): transport from PAH-loaded proximal tubular cells into the tubular lumen of the rat kidney in vivo. Pflügers Arch 1997; 433: 735-43.
22. Lipkowitz MS, Leal-Pinto E, Rappoport JZ, Najfeld V, Abramson RG. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 2001; 107: 1103-15.
23. Robertson WG. Urinary tract calculi. In: Nordin BEC, Need AG, Morris HA, Eds, Metabolic Bone and Stone Disease. Edinburgh: Churchill Livingstone, 1993: 249-311.
24. Matouschek E, Huber R. Ergebnisse einer internationalen kooperativen Studie uber das Harnsteinladen. Fortschr Urol Nephrol 1981; 17: 23-32.
25. Andersen DA. The nutritional significance of primary bladder stones. Br J Urol 1962; 34: 160-77.
26. Thalut K, Rizal A, Brockis JG, Bowyer RC, Taylor TA, Wisniewski ZS. The endemic bladder stones of Indonesia - epidemiology and clinical features. Br J Urol 1976; 48: 617-21.
27. Dick WH, Lingeman JE, Preminger GM, Smith LH, Wilson DM, Shirrell WL. Laxative abuse as a cause for ammonium urate renal calculi. J Urol 1990; 143: 244-7.
28. Nakamura K, Kokubo H, Kato K, Aoki S, Taki T, Mitsui K, et al. Ammonium acid urate urinary stone caused by a low-caloric diet: a case report. Hinyokika Kiyo 2002; 48: 483-6.
29. Klohn M, Bolle JF, Reverdin NP, Susini A, Baud CA, Graber P. Ammonium urate urinary stones. Urol Res 1986; 14: 315-8.
30. Atsmon A, De Vries A, Frank M. Uric acid lithiasis. Amsterdam: Elsevier, 1963.
31. Moran ME. Uric acid stone disease. Front Biosci 2003; 8: s1339-55.
32. Lavan JN, Neale FC, Posen S. Urinary calculi. Clinical, biochemical and radiological studies in 619 patients. Med J Aust 1971; 2: 1049-61.
33. Henneman PH, Wallach S, Dempsey EF. The metabolism defect responsible for uric acid stone formation. J Clin Invest 1962; 41: 537-42.
34. Metcalfe-Gibson A, McCallum FM, Morrison RB, Wrong O. Urinary excretion of hydrogen ion in patients with uric acid calculi. Clin Sci 1965; 28: 325-42.
35. Robertson WG. A risk factor model of stone-formation. Front Biosci 2003; 8: s1330-8.
36. Bambach CP, Robertson WG, Peacock M, Hill GL. Effect of intestinal surgery on the risk of urinary stone formation. Gut 1981; 22: 257-63.
37. Parks JH, Worcester EM, O'Connor RC, Coe FL. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 2003; 63: 255-65.
38. Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol 2002; 168: 1307-14.
39. Robertson WG, Peacock M, Hodgkinson A. Dietary changes and the incidence of urinary calculi in the U.K. between 1958 and 1976. J Chronic Dis 1979; 32: 469-76.
40. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int 2003; 64: 1022-6.
41. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-103.
42. Sakhaee K, Adams-Huet B, Moe OW, Pak CY. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 2002; 62: 971-9.
43. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004; 65: 386-92.
44. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int 2004; 65: 1422-5.
45. Robertson WG, Champenois I, Unwin RJ, Amiel J, Jaeger Ph. Diet and renal leaks in the pathogenesis of calcium nephrolithiasis - an integrated model. In: Gohel MDI, An DWT, Eds, Kidney stones: inside and out. Hong Kong: Hong Kong Polytechnic University Press 2004: 346-8.
46. Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 1993; 270: 354-9.
47. Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986; 30: 422-8.
48. Pak CY. Citrate and renal calculi: an update. Miner Electrolyte Metab 1994; 20: 371-7.
49. Gutman AB, Yü TF. Uric acid nephrolithiasis. Am J Med 1968; 45: 756-79.
50. Ordovas JM, Mooser V. Nutrigenomics and nutrigenetics. Curr Opin Lipidol 2004; 15: 101-8.
51. Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, Zarraga S, Calabozo M, Herrero-Beites AM, et al. Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant 2003; 18: 603-6.
52. Hart TC, Gorry MC, Hart PS, Woodard AS, Shihabi Z, Sandhu J, et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 2002; 39: 882-92.
53. Turner JJ, Stacey JM, Harding B, Kotanko P, Lhotta K, Puig JG, et al. Uromodulin mutations cause familial juvenile hyperuricemic nephropathy. J Clin Endocrinol Metab 2003; 88: 1398-401.
54. Bleyer AJ, Trachtman H, Sandhu J, Gorry MC, Hart TC. Renal manifestations of a mutation in the uromodulin (Tamm Horsfall protein) gene. Am J Kidney Dis 2003; 42: E20-6.
55. Dahan K, Devuyst O, Smaers M, Vertommen D, Loute G, Poux JM, et al. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol 2003; 14: 2883-93.
56. Kudo E, Kamatani N, Tezuka O, Taniguchi A, Yamanaka H, Yabe S, et al. Familial juvenile hyperuricemic nephropathy: detection of mutations in the uromodulin gene in five Japanese families. Kidney Int 2004; 65: 1589-97.
57. Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 2003; 42: 658-76.
58. Schlesinger N. Dietary Factors and Hyperuricaemia. Curr Pharm Design 2005; 11(32): 4133-38.
59. Schachter M. Uric acid, hypertension and dyslipidaemia. Curr Pharm Design 2005; 11(32): 4139-43.
60. Wannamethee SG. Serum Uric Acid and Risk of Coronary Heart Disease. Curr Pharm Design 2005; 11(32): 4125-32.
61. McMahon EG. Eplerenone, a new selective aldosterone blocker. Curr Pharm Design 2003; 9(13): 1065-75.
62. Moulder JE, Fish BL, Cohen EP. ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Curr Pharm Design 2003; 9(9): 737-49.
63. Wofford MR, Hall JE. Pathophysiology and treatment of obesity hypertension. Curr Pharm Design 2004; 10(29): 3621-37.